Coronavirus Update: Get the Latest News Here
Inbox
| x |
|
4:01 AM (9 hours ago)
|
| |||
Sunday, April 5, 2020
Coronavirus Update: Get the Latest News Here
THE ROLE OF A.I. &SUPER COMPUTERS IN COVID/CORONA vaccine and medicine
Mar 6, 2020 - The British AI start-up, owned by Google's parent company Alphabet, ... can take months but the use of machine learning could speed up that ... Scientists racing to create a potent vaccine against the virus need as ... It comes as the number of cases of coronavirus across the world ... Use our tool to find out ...
Mar 23, 2020 - How AI can help develop a drug to treat coronavirus ... In recent weeks, researchers at London-based BenevolentAI have been ... The likes of Sanofi, the French pharmaceutical giant, are now rolling out clinical trials for Covid-19 ... "
Mar 21, 2020 - AI is speeding up drug research. At the end of the day, the war on the novel coronavirus is not over until we develop a vaccine that can immunize ...
Mar 17, 2020 - Naturally, some believe that artificial intelligence may help. ... drugs, to the genetic properties of the virus and efforts to develop vaccines. ... The hope is that AI will accelerate insights into the novel coronavirus by ... publishers to open up research on the coronavirus, a number of big ... Require Opt-Out.
Mar 16, 2020 - Artificial intelligence can see "signals" in data earlier than humans, says the ... and researchers are speeding to discover, test and deploy a vaccine. ... we're we'
............................................................................................................................
Can distributed computing help speed up the coronavirus ...
https://www.weforum.org › covid-19-distributed-computing-vaccine
Mar 17, 2020 - A virtual supercomputer could speed up the search for a vaccine for COVID-19. ... “This is where you come in,” say the FAH researchers.
Mar 20, 2020 - This could help scientists create the most effective vaccine. ... The speed at which the virus spreads means they must accelerate their research.
Mar 24, 2020 - The consortium will be using an "unprecedented amount of computing power" to look at finding new COVID-19 treatments and ultimately vaccines ...
Mar 22, 2020 - ... at least 16 supercomputers to help speed the discovery of vaccines and ... will allow approved researchers to use powerful computing ... The announcement comes as health-care and government officials ... out, it has been downloaded over 18,000 times by researchers who ... Speed Up Your Home Wi-Fi.
Mar 14, 2020 - Scientists are using IBM's Summit, the world's fastest supercomputer, to help find promising candidate drugs to fight the coronavirus epidemic. ... Using the computer's muscle, researchers digitally simulated how 8,000 different ... GPUs can carry out more simultaneous operations than a CPU can, so leaning ...
Mar 27, 2020 - The announcement of this consortium comes on the coattails of the ... entire research community is ready, willing and eager to help assist ... Researchers can apply for access to the computers to run AI-assisted ... Another supercomputer collective that is taking on COVID-19 is the ... E-Newsletter Sign-up.
Mar 17, 2020 - Supercomputer-aided development of possible antiviral therapies, rapid lab ... and grants to develop new vaccine technologies: Coronavirus responses such as ... protein spikes on the outside of the virus make it look like the sun's corona. ... “
Wednesday, April 1, 2020
The Food and Drug Administration approval for testing kit by Bodysphere Inc. result for COVID-19 in 2 minutes.
The Food and Drug Administration issued an emergency approval Tuesday
for a serological testing kit produced by Bodysphere Inc. that can
detect a positive or negative result for COVID-19 in two minutes.
Why it matters: Access to testing has improved in the U.S. thanks to commercial labs, but the average wait time for a patient's results is four to five days — with some reports of it taking more than a week.
These antibody tests could help people know if they are able to go back to work, as well as aid researchers in tracking the scale and death rate of the disease — key data for current and future pandemic policies.
They're especially useful for determining whether health care workers have some immunity and are at lower risk if they go back to work.
Why it matters: Access to testing has improved in the U.S. thanks to commercial labs, but the average wait time for a patient's results is four to five days — with some reports of it taking more than a week.
These antibody tests could help people know if they are able to go back to work, as well as aid researchers in tracking the scale and death rate of the disease — key data for current and future pandemic policies.
They're especially useful for determining whether health care workers have some immunity and are at lower risk if they go back to work.
Yes, but: The
Bodysphere two-minute test can only detect the coronavirus in people
who have had the infection for several days, meaning the test can't be
used too early on when the body hasn't produced enough antibodies.
The big picture: The FDA has been rushing to approve tests from companies that promise quicker results.
Abbott Laboratories received emergency authorization last week to produce portable coronavirus tests, which the company indicates can detect the virus within five minutes.
The big picture: The FDA has been rushing to approve tests from companies that promise quicker results.
Abbott Laboratories received emergency authorization last week to produce portable coronavirus tests, which the company indicates can detect the virus within five minutes.
FDA Approves Anti-Malarial Drugs Chloroquine And Hydroxychloroquine For Coronavirus Treatment
FDA Approves Anti-Malarial Drugs Chloroquine And Hydroxychloroquine For Emergency Coronavirus Treatment
I cover breaking news.
A blister pack of Hydroxychloroquine sulfate pills is displayed on March 26, 2020, in London.
John Phillips/Getty Images
Topline: The Food and Drug Administration on Sunday issued an emergency authorization for experimental coronavirus treatments using chloroquine and hydroxychloroquine, anti-malaria drugs touted by President Donald Trump despite inconclusive clinical proof of their efficacy.
- The Department of Health and Human Services said Sunday hydroxychloroquine and chloroquine products can be distributed and prescribed by doctors through the Strategic National Stockpile “to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible.”
- HHS said Germany’s Sandoz has already given 30 million doses of hydroxychloroquine to the Strategic National Stockpile, the federal government’s inventory of medical supplies for public health emergencies, while Bayer has donated a million doses of chloroquine.
- The agency is fast-tracking a process that usually takes years while the FDA conducts clinical trials in New York, a hot spot for the virus.
- HHS said the emergency authorization was issued because the potential benefits of the product outweigh the risks and acknowledged that “anecdotal reports suggest that these drugs may offer some benefit in the treatment of hospitalized COVID-19 patients,” but cautioned that “clinical trials are needed to provide scientific evidence that these treatments are effective.”
- Trump had falsely claimed that the FDA had approved the drugs for coronavirus treatment before Sunday.
- Confusion over their use has led some Americans to seek over-the-counter replacements, such as an Arizona man who bought a nonpharmaceutical form of chloroquine phosphate, a common chemical used to clean fish tanks, which killed him and landed his now-widow in intensive care.
- The CDC warns against taking nonpharmaceutical chloroquine phosphate without a prescription and the supervision of a healthcare provider because it “can cause serious health consequences, including death.”
“It’s a difficult issue because it’s an emotional issue. With people having no other options available, it’s hard to say that if there’s something that seems like it may work, they should be denied the option to try it. The part that makes this more complicated is that there was an irresponsible, in my opinion, expression that this actually is effective when there is no real scientific evidence that it is,” Dr. Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development, told Forbes.
Today In: Forbes
News peg: Scientists hope chloroquine and hydroxychloroquine—decades-old drugs that are used to treat malaria, lupus and rheumatoid arthritis—may be used to treat the coronavirus, but early studies have provided mixed evidence proving their effectiveness and the drugs may entail risks such as vision problems or cardiac arrest. The frenzy surrounding the treatment has caused some doctors to hoard hydroxychloroquine—which is sold under the brand name Plaquenil—by writing prescriptions for themselves or for their families. Some state pharmacy boards have issued rules limiting prescriptions, including Texas, Louisiana, Ohio and North Carolina.
Tuesday, March 31, 2020
WebMD; News Brief:-FDA Authorizes Rapid-Result (within 5 minutes.)Coronavirus Test
FDA Authorizes Rapid-Result Coronavirus Test
March 30, 2020 - The FDA has authorized a coronavirus test that the manufacturer says can tell if someone is infected with the virus within 5 minutes.In a news release, Abbott Diagnostics Scarborough in Illinois said the test can tell if a person has the coronavirus in as little as 5 minutes and tell if someone doesn't have the virus in 13 minutes.
A shortage of tests has hindered efforts to contain the virus in the U.S, which leads the world with more than 100,000 cases of COVID-19. Testing has been focused on priority groups, such as hospitalized patients and health care professionals with symptoms, according to CDC guidelines.
Abbott said it will make the tests available to health care providers next week and work with the government to send the tests to areas where they're most needed.
Sunday, March 29, 2020
use 3Dprinting tech:to mass produce mask&ventilator
use 3Dprinting tech:to mass produce mask&ventilator
FIRST 3D PRINT NEW 3D PRINTERS ;
THEN USE THE 3D PRINTERS TO MASS PRODUCE MASKS ;GLOVES;VENTILATORS
3D-printer companies build face shields, masks, more to fight ...
5 days ago - Most 3D printers today are best suited to making plastic parts, not cloth or filters used in face masks. Based in Redwood City, California, Carbon is ...
5 days ago - HP 3D Printed Masks for COVID-19 response; Designed by research institute CIIRC CVUT ... A single print can produce 300 test swabs at a time enabling ... frequently reviewing 3Dprinters and sharing his technical expertise.
Mar 20, 2020 - Manufacturers such as Vauxhall and Airbus are planning to repurpose their factories and utilize 3D-printing technology to create parts for ventilators to treat patients with the coronavirus.
RELATED NEWS
2 days ago - Formlabs' 3D printed nasal swab for COVID-19 tests. Courtesy: Formlabs. In normal times, Formlabs sells 3D printers, not ...
1 day ago - In one week, the group designed, made, tested, and are now distributing 3D-
3 days ago - 3D Printer Crowdsourcing for COVID-19 public spreadsheet; Useful 3D Files; Cad Crowd's 3D Printing Challenge. Update 3/27. As the global 3D ...
3 days ago - The brand's Covid-19 masks consist of a visor that is worn across the forehead and secured behind the ears with elastic. Clear plastic film is ...
5 days ago - HP 3D Printing Covid-19. (Image credit: HP). HP has revealed plans on how it is using its 3D printers and expertise to help fight coronavirus, ...
How 3D printing can affect your broken supply chain during the crisis caused by the Covid-19 outbreak? 3D printing VS coronavirus. Worldwide pandemic ...
3 days ago - The additive manufacturing and 3D printing community has many members keen to assist during the COVID-19 pandemic. This is a summary of ...
3 days ago - 3D printing in support of COVID-19 containment efforts. Producing critical parts to help meet urgent needs. Materials on these pages are being ...
1 day ago - Top 1: COVID-19, how is 3D printing helping the fight? Given the current health crisis, the 3D printing community has mobilized to curb the ...
Saturday, March 28, 2020
These 5 anti-viral drugs and therapies could help treat COVID-19
These 5 anti-viral drugs and therapies could help treat COVID-19
Researchers and pharmaceutical giants across the world are scrambling to find a cure for coronavirus which has been declared a pandemic.
The World Health
Organization (WHO) has launched global clinical trials to test possible
treatments for COVID-19 across 10 countries as a “solidarity trial”.
Some of the treatments to be tested are drugs already being used for other illnesses like HIV, Ebola and malaria.
Top drugs under trial include anti-malarial medicine chloroquine,
anti-viral drug remdesivir, a combination of HIV drugs lopinavir and
ritonavir, as well as a combination of the latter two drugs infused with
Interferon beta.Also read: Vaccine trials to contact tracing app — here are 5 global developments on COVID-19 front
Anti-malaria drug chloroquine
The popular anti-parasitic medication which treats malaria has been around since the 1940s. US President Donald Trump Thursday called it a “game changer”, and proposed its use for COVID-19 cases.
However, American drug regulator, Food and Drug Administration (FDA), said “the agency is currently looking at widespread clinical trials of the drug, but it is not yet approved for that use”.
Biotech investor and doctor Mike Pellini was the first to use chloroquine as a possible cure for coronavirus.Chloroquine works by increasing the levels of haem or heme — a substance toxic to the malarial parasite — in the blood. This kills the parasite and stops the infection from spreading.
According to some earlier studies, “chloroquine has strong antiviral effects on SARS-CoV infection of primate cells”. One study showed that chloroquine interferes with “terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2”, which may negatively influence the virus-receptor binding and abrogate the infection.
Chloroquine is widely available in India, and is manufactured by several local companies including Ipca Laboratories, Alembic Pharmaceutricals and Cadila Pharmaceuticals.
If the drug works as a cure for the novel coronavirus, scaling up production won’t be difficult.
Foreign drug makers like Abbott, Bayer and Leo Pharmaceuticals also sell this drug in India.
Also read: 10-year-old US firm with Harvard and MIT brains begins first COVID-19 vaccine trials
Ebola drug remdesivir
Another drug in the spotlight is remdesivir — an anti-viral developed by drugmaker Gilead, which specialises in manufacturing anti-HIV drugs.According to the WHO, remdesivir may have the best shot at treating COVID-19.
Remdesivir is an investigational broad-spectrum anti-viral drug, which was developed to fight the Ebola virus. It is currently undergoing clinical trials on coronavirus patients in China. WHO expects the trial data to be available within weeks, according to media reports.
At a press briefing in Beijing, WHO assistant director-general Bruce Aylward said: “There is only one drug right now that we think may have real efficacy, and that’s remdesivir.”
It was previously tested on humans with the Ebola virus disease, and has shown promise in animal models for treating Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), which are caused by other coronaviruses.
Also read: Govt sets up science and tech core team to coordinate efforts against coronavirus
Japanese flu pill favipiravir
According to a report in The Guardian which, in turn, quoted a Japanese media report, “medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients”.The reports said doctors in Japan are using the drug in clinical studies on COVID-19 patients with mild to moderate symptoms. However, the drug has not shown great results on patients with severe symptoms.
The reports quoted Zhang Xinmin, an official in China’s science and technology ministry, as saying: “Favipiravir, developed by a subsidiary of Fujifilm with brand name Avigan, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.
“It has a high degree of safety and is clearly effective in treatment,” Xinmin said.
The use of favipiravir showed definite improvements in lung condition in 91 per cent of the patients treated with it, compared to 62 per cent of those treated without the drug.
Also read: One coronavirus patient infects 1.7 people in India, much lower than in China, Italy: Study
Plasma therapy
The US FDA is currently evaluating therapies such as convalescent plasma and hyperimmune globulin. These are antibody-rich blood products are taken from the blood donated by people who have recovered from COVID-19. Research is going on to check if these products “could shorten the length, or lessen the severity, of the illness”.Japanese drugmaker Takeda Pharmaceutical is also developing a therapy against the coronavirus using blood plasma. Bloomberg reported that with its background in manufacturing immunoglobulin-based products approved by top regulating bodies across the globe, including the US FDA, “the Japanese pharmaceutical company could have an edge because the treatment involves a process that already has approval from regulators”.
However, Takeda has not yet tested the therapy on any COVID-19 patients.
Also read: No new cases in China to clean Venice waters — the latest on COVID-19
Combination of HIV drugs
Several patients across the globe have reported benefits from treatment with a combination of HIV drugs — lopinavir and ritonavir.Lopinavir, which acts against the viral 3CL protease, has modest anti-viral activity against SARS-CoV-2 (the novel coronavirus), according to an study published in The New England Journal of Medicine (NEJM).
“Together with ritonavir, which increases drug bioavailability, it is in clinical trials, along with the immunomodulator interferon beta-1b, for the treatment of Middle East Respiratory Syndrome (MERS),” the article stated.
In India, the Union health ministry has also recommended the use of anti-HIV drug combinations for high-risk groups of patients, but there is no current evidence from randomised controlled trials to recommend a specific treatment.
However, according to another study published in the NEJM, these drugs have failed to cure COVID-19. A clinical trial in Beijing tested the lopinavir-ritonavir combination on people who were severely ill, but the outcomes of 94 people who received them were no different from 100 patients who received standard care, the study stated. However, it drew an open-ended conclusion.
“In hospitalised adult patients with severe COVID-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit,” the study said.
Subscribe to:
Posts (Atom)